SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?


To: Daniel Shaffer who wrote (159)12/16/1998 7:22:00 AM
From: flickerful  Read Replies (1) | Respond to of 2515
 
beyond
any sell on the news mentality,
and notwithstanding any general market malaise,
tax selling wise, or otherwise...i believe the trading was tmexicizedand then left for dead.

in any event,
this action reflected daytrading syndrome,
and i suspect the consequent selling pressure was unusual.



To: Daniel Shaffer who wrote (159)12/16/1998 1:01:00 PM
From: 5,17,37,5,101,...  Read Replies (1) | Respond to of 2515
 
Good question DS, and I don't have an answer for you. I am a holder of IMCL since $4 (having sold all at $11+ in July and recently repurchased below $10) and have seen this stock whipped up and down radically. Investors are awaiting substantial news regarding prospective drugs. The news of Merck's investment is more of the same and expected by investors. There are all sorts of rumors out there of magical drugs that eliminate cancer (Geron), but investors are awaiting concrete evidence with IMCL. Why are they waiting? Why no hype here? I can't say except that maybe C225, because it is a taxol based drug, will have to compete with a myriad of other taxol based drugs out there (BMY, IVX) to name a couple of companies producing taxol based drugs -- there are several others. When IMCL can show that C225 produces vastly superior results to competing drugs the stock should rise dramatically. The competition in this area is pretty fierce.

Jackson